Circassia Pharmaceuticals PLC (LON:CIR) had its price target reduced by JPMorgan Chase & Co. from GBX 170 ($2.22) to GBX 140 ($1.83) in a research note released on Wednesday. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company’s stock.
Other equities analysts have also issued reports about the company. Stifel Nicolaus restated a buy rating and set a GBX 375 ($4.89) price target on shares of Circassia Pharmaceuticals PLC in a research note on Monday, June 20th. Peel Hunt downgraded Circassia Pharmaceuticals PLC to an add rating and decreased their price objective for the company from GBX 509 ($6.64) to GBX 160 ($2.09) in a report on Tuesday, June 21st. Numis Securities Ltd reaffirmed a buy rating and set a GBX 150 ($1.96) price objective on shares of Circassia Pharmaceuticals PLC in a report on Tuesday. Royal Bank Of Canada downgraded Circassia Pharmaceuticals PLC to a sector performer rating and decreased their price objective for the company from GBX 430 ($5.61) to GBX 105 ($1.37) in a report on Tuesday, June 21st. Finally, Barclays PLC started coverage on Circassia Pharmaceuticals PLC in a report on Tuesday, June 21st. They set an overweight rating and a GBX 170 ($2.22) price objective on the stock. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Circassia Pharmaceuticals PLC has an average rating of Buy and an average target price of GBX 183.33 ($2.39).
Shares of Circassia Pharmaceuticals PLC (LON:CIR) traded up 1.07% during trading on Wednesday, hitting GBX 94.50. The stock had a trading volume of 129,508 shares. The stock’s market capitalization is GBX 269.12 million. The stock’s 50 day moving average is GBX 94.79 and its 200 day moving average is GBX 179.06. Circassia Pharmaceuticals PLC has a 52 week low of GBX 81.05 and a 52 week high of GBX 322.90.
Circassia Pharmaceuticals PLC Company Profile
Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates.
Receive News & Ratings for Circassia Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.